0.9103

1.08% -0.0099

After Hours: .91 -0.0003 -0.03%

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $0.9103, with a volume of 158.00K. It is down -1.08% in the last 24 hours and down -12.05% over the past month. Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Previous Close:

$0.9202

Open:

$0.9

24h Volume:

158.00K

Relative Volume:

1.17

Market Cap:

$5.39M

Revenue:

Net Income/Loss:

$-15.52M

P/E Ratio:

-0.049

EPS:

-18.58

Net Cash Flow:

$-16.61M

1W Performance:

+13.82%

1M Performance:

-12.05%

6M Performance:

-64.71%

1Y Performance:

-90.70%

1-Day Range:

$0.8701

$0.9303

1-Week Range:

$0.77

$0.9303

52-Week Range:

$0.702

$9.60

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1116)

Industry

Biotechnology (620)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	0.9103	5.45M	0	-15.52M	-16.61M	-18.58
VRTX Vertex Pharmaceuticals Inc	484.15	118.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	812.27	81.61B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	422.50	53.69B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.94	49.49B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	176.00	37.34B	447.02M	-1.18B	-906.14M	-6.1812

Revelation Biosciences Inc Stock (REVB) Latest News

09:54 AM

Revelation Biosciences begins GMP manufacturing for GEMINI trials By Investing.com - Investing.com Nigeria

09:54 AM

09:03 AM

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Weatherford Democrat

09:03 AM

09:00 AM

Potential acute kidney injury drug moves toward larger clinical trials - Stock Titan

09:00 AM

Jan 05, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 - Lubbock Avalanche-Journal

Jan 05, 2026

Jan 01, 2026

Published on: 2026-01-01 23:42:59 - bollywoodhelpline.com

Jan 01, 2026

Price Action: How Revelation Biosciences Inc stock performs after earnings2025 Support & Resistance & Reliable Momentum Entry Alerts - moha.gov.vn

Jan 01, 2026

Dec 31, 2025

Viking Therapeutics (NASDAQ:VKTX) and Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast - Defense World

Dec 31, 2025

Dec 29, 2025

Marshall Machines Limited (MARSHALL) Expands into New MarketTrading Psychology Tips & Low Risk Capital Growth Plans - bollywoodhelpline.com

Dec 29, 2025

Dec 27, 2025

Revelation Biosciences on track for end-of-phase 1 meeting later this year - MSN

Dec 27, 2025

Dec 26, 2025

Revelation Biosciences reaches quorum for Dec. 3 special meeting - MSN

Dec 26, 2025

Dec 24, 2025

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year - Reno Gazette Journal

Dec 24, 2025

Dec 23, 2025

Total debt per share of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView — Track All Markets

Dec 23, 2025

Dec 21, 2025